//fpnotebook.com/
Short-Acting Anticholinergic Bronchodilator
Aka: Short-Acting Anticholinergic Bronchodilator, Short-Acting Muscarinic Antagonist, Ipratropium, Ipratropium Bromide, Atrovent, Combivent, Combivent Respimat
- Indications
- Chronic Obstructive Pulmonary Disease (COPD)
- Asthma
- Mechanism
- Short-Acting Anticholinergic Bronchodilator
- Preparations: Ipratropium Bromide
- Atrovent MDI: 2-3 puffs three to four times daily
- Atrovent Nebulization: 1 ampule in nebulization solution every 6 hours prn
- Preparations: Combination Ipratropium with Albuterol (Combivent)
- Combivent (older CFC version)
- Will be phased out in 2013 due to CFC
- Dose: 2 puffs up to every 6 hours
- Contraindicated in soybean or peanut allergy
- Combivent Respimat
- Dose: 1 puff every 6 hours
- Does not carry the Food Allergy related contraindications of the older Combivent
- Adverse Effects
- Serious adverse effects
- Anaphylaxis, Angioedema or other Hypersensitivity Reaction
- Paradoxical bronchospasm or Laryngospasm
- Exacerbation of Glaucoma
- Increased cardiovascular events
- Avoid short acting Anticholinergics (Ipratropium) in comorbid cardiovascular disease
- Ogale (2010) Chest 137(1): 13-19 [PubMed]
- Singh (2008) JAMA 300(12): 1439-50 [PubMed]
- Common adverse effects
- Cough
- Dry Mouth or oral irritation
- Gastrointestinal upset such as Nausea
- Urticaria or other rash
- Headache
- Nervous sensation